ENDOREX CORP
10QSB, EX-27, 2000-08-14
PHARMACEUTICAL PREPARATIONS
Previous: ENDOREX CORP, 10QSB, EX-10.2, 2000-08-14
Next: ENDOREX CORP, 10QSB, EX-99.1, 2000-08-14



<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<LEGEND> This schedule contains summary financial information extracted from
the consolidated balance sheet and consolidated statement of operations and is
qualified in its entirety by reference to such financial statements.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                         DEC-31-2000
<PERIOD-START>                            JAN-01-2000
<PERIOD-END>                              JUN-30-2000
<CASH>                                     10,170,382
<SECURITIES>                                4,030,281
<RECEIVABLES>                                       0
<ALLOWANCES>                                        0
<INVENTORY>                                         0
<CURRENT-ASSETS>                           14,379,141
<PP&E>                                      1,150,228
<DEPRECIATION>                              (723,389)
<TOTAL-ASSETS>                             15,012,487
<CURRENT-LIABILITIES>                       2,111,497
<BONDS>                                             0
                       9,344,530
                                 9,667,159
<COMMON>                                       12,861
<OTHER-SE>                                (6,394,699)
<TOTAL-LIABILITY-AND-EQUITY>               15,012,487
<SALES>                                             0
<TOTAL-REVENUES>                              320,965
<CGS>                                               0
<TOTAL-COSTS>                             (1,449,714)
<OTHER-EXPENSES>                          (1,578,855)
<LOSS-PROVISION>                                    0
<INTEREST-EXPENSE>                           (23,020)
<INCOME-PRETAX>                           (2,730,624)
<INCOME-TAX>                                        0
<INCOME-CONTINUING>                       (2,730,624)
<DISCONTINUED>                                      0
<EXTRAORDINARY>                                     0
<CHANGES>                                           0
<NET-INCOME>                              (2,730,624)
<EPS-BASIC>                                    (0.29)
<EPS-DILUTED>                                  (0.29)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission